Curtis Hagedorn, MD
Ophthalmology · Denver, CONPI 1508863382
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $15,430 of the $25,066 with a category attached, or 61.6%. US Retina LLC accounts for 61.6% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $11,646 and has fallen 90.9% since, to $1,054 in 2025. Among ophthalmology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 73 payments — averaging $343.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$15K
- Regeneron$6K
- AbbVie$937
- Genentech, Inc.$909
- Astellas Pharma US Inc$453
- Genentech USA, Inc.$411
- plus $922 from 9 others
Across 238 payments — averaging $6403.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$979K
- Amgen$198K
- Regeneron$180K
- Boehringer Ingelheim$127K
- Janssen Research & Development, LLC$37K
- Boehringer Ingelheim International GmbH$4K
What the payments were for
- Consulting fees$5,40022%
- Grants$830%
- Food & beverage$3,40314%
- Education$7503%
- Ownership interest$15,43062%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 4 | $15,430 |
| Regeneron | 6 | $6,005 |
| AbbVie(2 entities) | 9 | $937 |
| Genentech, Inc. | 5 | $909 |
| Astellas Pharma US Inc | 14 | $453 |
| Genentech USA, Inc. | 17 | $411 |
| Regeneron Healthcare Solutions, Inc. | 3 | $285 |
| Astellas Pharma Global Development | 1 | $164 |
| Ocular Therapeutix, Inc. | 1 | $150 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $75 |
| Novartis | 4 | $72 |
| Alimera Sciences, Inc. | 4 | $71 |
| Eyepoint US, Inc. | 1 | $55 |
| Biogen | 2 | $34 |
| Bausch & Lomb Americas Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,066 in reported general payments places this provider in the 90th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 112 | $4,242 |
| Ofloxacin | 87 | $869 |
| Ketorolac Tromethamine | 12 | $408 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Denver
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
- Michael JansenDenver$95K
- Kingsley OkaforDenver$62K
- Michael SolomonDenver$12K
- Peter HovlandDenver$10K
- Matthew KrugerDenver$8K
- Stuart LewisDenver$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.